{"name":"Alcon, a Novartis Company","slug":"alcon-a-novartis-company","ticker":"","exchange":"","domain":"","description":"Alcon, a Novartis Company, is a global leader in eye care, dedicated to helping people see better through innovative products and solutions. The company focuses on surgical and vision care, offering a wide range of products including intraocular lenses, surgical devices, and contact lens solutions.","hq":"","founded":0,"employees":"~27,000","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Subject's habitual PGA monotherapy","genericName":"Subject's habitual PGA monotherapy","slug":"subject-s-habitual-pga-monotherapy","indication":"Open-angle glaucoma","status":"marketed"}]}],"pipeline":[{"name":"Subject's habitual PGA monotherapy","genericName":"Subject's habitual PGA monotherapy","slug":"subject-s-habitual-pga-monotherapy","phase":"marketed","mechanism":"PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQNG1Zbl9QaXdEbmFvWXBTWmZRWEJFN2IxU19zQk01bkpmNDUwTFVCa0VETWVib1ZsMHNuZmpIT3JvQXU3ZWNTbzU3M0JOU2hvd3daWUdWT1ktT0hmOC1VWl93bFIzRXhkdHM4YzVqenhEZlBoZHd6M1BvQWR1Q0UyQnVXZ2lQZw?oc=5","date":"2025-08-07","type":"pipeline","source":"Yahoo Finance","summary":"Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical -","headline":"Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObTMydGNtQlFXLUpDMGxFSmNoUW8zdVhYcW85aVhWU3lrb2Flem1KNEtHWmVnTDJ4ZzA2dV9xUnlVZVpIOVRVUlhKa3ZqbkVhUFpCY2s5Q2xqNTU0dmJxZEdWMjRrV1FBY084eGMySEdJSjJxb28zWVRYZnliSjZIZk5lU1FEdlBEdkUyUmx0NC1WcjRneElLVlBSVng3d2FOMGZLcVhmM2tTUQ?oc=5","date":"2025-05-29","type":"regulatory","source":"Fierce Pharma","summary":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease - Fierce Pharma","headline":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPS2xtdjMzNGdObU1BcG5Mc0JhdWlrNGxzN2xKMUF2YXNKS2pfNGVXZ1FRUFlJbWJHOGpJOGV1S0tNNXNRSkVzLVZXR3ZPajhMX0EwVHZqZ3E3TnJvWDFkWUtMNDBhR0VoRzh4NTVHWmVtanN2TlFDQ1h0d2ZBVkxmVTM3VGJQa2hmUGpCVUNIczRIanAtRnZr?oc=5","date":"2022-11-22","type":"pipeline","source":"Ophthalmology Times","summary":"Alcon completes acquisition of Aerie Pharmaceuticals - Ophthalmology Times","headline":"Alcon completes acquisition of Aerie Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNRHhQREpzM0Rwd28yU053c1pfWVhiZWlUb29GT09WeVVRckh4am9aQzhrTHpuQ2QzdGt6TXg0Ym9fdlBfV0ZkTlFJRmFxdHhibGllRklsQ2NkRlFrVXV3SWtZb09temdLS0dUbklIY0ZqWDc5d0hESUk4X1E1VmozaVJBUllkandSbkNWR0cxQUludXpUQVZUUGhDejhiYXNiV0hoVGRTVDRDY3VHOVljWFo5SDQ4SDRjSG9wMXRLUlpVcGhL?oc=5","date":"2019-04-09","type":"pipeline","source":"Novartis","summary":"Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off - Novartis","headline":"Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQQVlQcnBiTmVvWmZQenl5ZW16cW0tV1dwMjhoSEFPQWFJV1lveDZpeUViXy13UElNVENTeWk1VEpzVEpqSlBSM3JzSEtGeG91TjdRUFV1cEMwMEdsOEd6UXl4Z2hLVU1NREN2S3piaGFXdkF1bTBsc2d5WEExVFJnWDU0d0l2anlCX1NvWjlCeHB3MmtYVy1LblNiWTVCR0h0TE1iVmFhbw?oc=5","date":"2019-04-09","type":"regulatory","source":"BioPharma Dive","summary":"Alcon spin-out marks step in Novartis plan to remake business - BioPharma Dive","headline":"Alcon spin-out marks step in Novartis plan to remake business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNaEt1TWg0MVZ0N0JBQjdxYngwV3ZPOGFEejJNZGJDZ21tZmFlNHlLbnhLbTBHbVYtZnNybHJIS0QzWmlKbk9SZ2NtQVFpWUx2RzZ6UkdqOHRRSHV0S0htZGF6REQ4UXRXT0RNdjJaQkNaWThxMkQ0RXRZclVnWGRXZ3BCSQ?oc=5","date":"2019-04-09","type":"pipeline","source":"BioSpace","summary":"Out From Under Novartis, Alcon Is Its Own Company Now - BioSpace","headline":"Out From Under Novartis, Alcon Is Its Own Company Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE94WDA3UGV1OVJtc3NNbVNsaWNkYVNrSXdGeWN1a3lmSVpyeGJQSXdMdDY1RHk2N001eXRpOG5xUnNjTUZlc1dxVnZvNzJkeUxCdldKSUFaTEFCVXRid0pHS29CQ3VmU2xxTUtkZzFrNWVzX0Q5?oc=5","date":"2019-03-22","type":"pipeline","source":"BioSpace","summary":"Alcon to Officially Spin out From Novartis on April 9 - BioSpace","headline":"Alcon to Officially Spin out From Novartis on April 9","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOWmo5amRLT3YtTjdsejF2N29zaVN5aDFQMkE2ZXFQMGpnZXAzY3lfSEtCQ2xGU1ZBRnpWT1E0N3NGaVV3T1NfemJucGswbVpDdlVSOHpyOGNpNEpiUm9WaHBfMUFpa1Z3ZDNNX1JVTkNEM2JtY2dXTDl3OE55ekZkM1EtUVRwWFFBMkZvZGhrOFI5SXZiVlg1WXBVMA?oc=5","date":"2019-03-22","type":"pipeline","source":"Fierce Pharma","summary":"Alcon will officially leave Novartis on April 9 after an 8-year run. What's next? - Fierce Pharma","headline":"Alcon will officially leave Novartis on April 9 after an 8-year run. What's next?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdGxKZXMyVlFrVFctb29Ta3JfeHdKd2FQVFZzY3AtdVZvbzZVczBSMjk0OE1ER0VsRXp5djN2alJFcExJZjNLdGZMS3R4dVZzZy1FTVBiQW5vanpBU1QwdlBYaDBQazVkeHF4T0dQZmVrdGxmTFd4a0VWb1BtdmJKNS1IWkF0bVZjWkJwTktEUXA0TnNnSGk2VVQ4ZmJJdDVlR0E?oc=5","date":"2018-06-29","type":"pipeline","source":"BioPharma Dive","summary":"Novartis to spin out Alcon into standalone device company - BioPharma Dive","headline":"Novartis to spin out Alcon into standalone device company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNUGNqU3dxYjVoQVl2WFdVVkV5OTI0WFh3VnZmNXBucHlmc0pjY29JYkVYdWF2SlNqV3FKNWFGYWdNbG80ZWFlSXBzcmVGSl9xN2tIR0cxU2VLS1dZTTBCQnFEUERzNF95ekZORUVkWWZ5OVNkaEVUNVFJMlo0NEhiZW43RmtFTHBvclkyNVNqdw?oc=5","date":"2018-06-29","type":"pipeline","source":"Drug Delivery Business","summary":"Novartis to spin out Alcon ophthalmic subsidiary - Drug Delivery Business","headline":"Novartis to spin out Alcon ophthalmic subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxOaTlqMnNqbjJRWndSamJyUks1Nl9pRkc5NUZyNUZVdnFXSkcybm5jNDdxOTBYeG5aZllXMG1lTzdvc0t2QzBDenVJZHBpRm43VmVTYktxdWprb0gxNmRuM3hjNUhDWDcwR3B4UEh3cDlSekNnT1o4cmhzTkZMQnpsY3pfTXY2WndFWHhiRXBkVWZISXliTmtGZHJKSUdVdEFHSXVya25UUWFLc01rdzExM0FDWHdZUklacTF4YXVxZVZfUXh2VV9CcnQyVDFlZDMyMl9rLTNaNVlBYWE3dGVnTVpybmdla0ZCaGtJNXJ0T2t5aGtOallRQWVYLXlrWlN5ckR4TEFrRQ?oc=5","date":"2018-06-29","type":"regulatory","source":"Novartis","summary":"Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn - Novartis","headline":"Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNRWxEN3NQX1JzelQ0eHQtNjJVMzhkTHVCS2dPTTMyTlVsS19YaUlqR3V1SkpLQmZvS01KOWl6N3B5OU9CNnRjaHh2Zk5Tdy14RlcxSk8wMEYzNFN4TXVQS0ZLZkR1Y2NHQWluQVNxNFBFaXF0MEdlQ3Zrb3dzZXVPM1FRdXF1Z1R5VFFvRFRWdXZ5MW5sdGZaczZwM2xMZFZMd0U4aUlVTkk0SG1QVU5nSnJCRVVpeGJDaV9kQXFnRS1WSEVrVzllMDJsbXZILUk?oc=5","date":"2016-01-11","type":"pipeline","source":"Reuters","summary":"No quick fix seen for Novartis's troubled Alcon unit - Reuters","headline":"No quick fix seen for Novartis's troubled Alcon unit","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}